169 related articles for article (PubMed ID: 36875089)
1. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.
Zheng X; Gu H; Cao X; Pan B; Xiang H; Ju M; Xu S; Zheng M
Front Immunol; 2023; 14():1113369. PubMed ID: 36875089
[TBL] [Abstract][Full Text] [Related]
2. Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
Wang Z; Bi H; Wang YD; Liu Q; Shao B; Li CQ; Fu C; Fu S; Shan GY; Chen A; Lv CC; Zeng Y
Actas Urol Esp (Engl Ed); 2024 May; 48(4):295-303. PubMed ID: 38160794
[TBL] [Abstract][Full Text] [Related]
3. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
[TBL] [Abstract][Full Text] [Related]
4. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study.
Ren X; Tian Y; Wang Z; Wang J; Li X; Yin Y; Chen R; Zhan Y; Zeng X
BMC Urol; 2022 Aug; 22(1):128. PubMed ID: 35987640
[TBL] [Abstract][Full Text] [Related]
5. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
6. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
7. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.
Jiang Y; Gu H; Zheng X; Pan B; Liu P; Zheng M
Pathol Oncol Res; 2021; 27():1609946. PubMed ID: 34992504
[No Abstract] [Full Text] [Related]
9. The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study.
Wu M; Zheng X; Wang X; Li X; Zhang Y; Zhao J
Cancer Control; 2023; 30():10732748231173475. PubMed ID: 37115019
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.
Ye D; Liu J; Zhou A; Zou Q; Li H; Fu C; Hu H; Huang J; Zhu S; Jin J; Ma L; Guo J; Xiao J; Park SH; Zhang D; Qiu X; Bao Y; Zhang L; Shen W; Bi F
Cancer Sci; 2021 Jan; 112(1):305-313. PubMed ID: 33047430
[TBL] [Abstract][Full Text] [Related]
11. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
12. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
[TBL] [Abstract][Full Text] [Related]
13. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
14. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
15. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y; Pan J; Wang H; Zhao Y; Qu S; Chen N; Chen X; Sun Y; He X; Hu C; Lin L; Yu Q; Wang S; Wang G; Lei F; Wen J; Yang K; Lin Z; Guo Y; Chen S; Huang X; Wu Y; Liang L; Chen C; Bai F; Ma X; Zhang Y; Leaw S; Zhang L; Fang W
Cancer Cell; 2023 Jun; 41(6):1061-1072.e4. PubMed ID: 37207654
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab for the treatment of classical Hodgkin's lymphoma.
Chen J; Zhang H; Zhu L; Zhao Y; Ding Y; Yuan Y
Drugs Today (Barc); 2020 Dec; 56(12):781-785. PubMed ID: 33332484
[TBL] [Abstract][Full Text] [Related]
17. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study.
He Q; Shi X; Yan J; Wu M; Gu C; Yu X
Mol Clin Oncol; 2024 Apr; 20(4):29. PubMed ID: 38414510
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
20. A real-world evaluation of tislelizumab in patients with head and neck cancer.
Zheng B; Huang Z; Liu W; Zhao D; Xu X; Xiao S; Sun Y; Wang W
Transl Cancer Res; 2024 Feb; 13(2):808-818. PubMed ID: 38482433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
